• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-SUMO2/3

SUMO2/3 Monoclonal Antibody for WB, IHC, IF/ICC, Indirect ELISA

Hôte / Isotype

Mouse / IgG2b

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1A1B3

N° de cat : 67154-1-PBS

Synonymes

SUMO2, Small ubiquitin-related modifier 2, Sentrin-2, Sentrin2, Sentrin 2



Informations sur le produit

67154-1-PBS cible SUMO2/3 dans les applications de WB, IHC, IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Mouse / IgG2b
Clonalité Monoclonal
Type Anticorps
Immunogène SUMO2/3 Protéine recombinante Ag28672
Nom complet SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)
Masse moléculaire calculée 11 kDa
Poids moléculaire observé 18 kDa
Numéro d’acquisition GenBankBC008450
Symbole du gène SUMO2
Identification du gène (NCBI) 6613
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Ubiquitin is most famous for its function in targeting proteins for degradation by the 26S proteasome, ubiquitin needs to be attached to a substrate in chains (polyubiquitylation) before being recognized by proteasome. Similarly, SUMO (small ubiquitin-related modifier) can be linked to substrates in chains (polysumoylation), SUMO modification has been implicated in many important cellular processes including the control of genome stability, signal transduction, targeting to and formation of nuclear compartments, cell cycle and meiosis. There are 4 confirmed SUMO isoforms in human, SUMO-1, SUMO-2, SUMO-3 and SUMO-4. SUMO-2 and SUMO-3 are nearly identical but are distinct from SUMO-1. SUMO2/3 conjugation was recently widely involved in neuroprotective activities. A substitution (M55V) of SUMO4 was strongly associated with the pathogenesis of type 1 diabetes (T1D) involving NF kappa B related mechanisms.

{{ptg:RelatedPrimaryAntibodies}}